Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CK-101 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Daily dose of CK-101 | EXPERIMENTAL | Daily oral dose of CK-101 |
| Name | Type | Description |
|---|---|---|
| CK-101 | DRUG | Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles Phase 2: CK-101 will be administered daily |
Inclusion Criteria: * Measureable disease according to RECIST Version 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Minimum age of 18 years * Adequate hematological, hepatic and renal function * Written consent on an Institutional Review Board-approved informed cons...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
CK-101 is an investigational small molecule drug being developed by Fortress Biotech, Inc. for lung neoplasms, specifically non-small-cell lung cancer and other advanced solid tumors. It is designed to target EGFR, a receptor that is a biomarker-selected target in this program. CK-101 remains in clinical development and is not approved for commercial use.
CK-101 is being studied for the treatment of lung neoplasms, including non-small-cell lung cancer and adenocarcinoma, as well as other advanced solid tumors. The program enrolls patients whose tumors are biomarker-selected for EGFR. It is an investigational therapy and has not been approved for any indication.
CK-101 targets EGFR, a receptor tyrosine kinase. EGFR is a receptor-class molecular target, and the CK-101 clinical program is biomarker-selected, meaning patients are chosen based on EGFR-related tumor characteristics. This targeted approach is intended to focus treatment on tumors driven by EGFR signaling.
CK-101 is being developed by Fortress Biotech, Inc., which trades on the Nasdaq under the ticker FBIO. Fortress Biotech is the sponsor of the CK-101 clinical program in lung neoplasms and other advanced solid tumors.
CK-101 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA or any other regulatory agency. The single registered trial for CK-101 has been completed, and no trials are currently listed as active.
CK-101 has been evaluated in one registered clinical trial, NCT02926768, titled Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors. The trial enrolled 136 patients across the United States, Australia, New Zealand, Poland, and Thailand, and its status is completed. It was an uncontrolled study without randomization or double blinding.